跳至主要内容
临床试验/NCT02840331
NCT02840331Unknown3 期

Pilot Study on Intra-abdominal Photodynamic Diagnosis in Peritoneal Carcinosis

University Hospital Tuebingen1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2017年7月31日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
入组人数
50
试验地点
1
主要终点
Peritoneal metastases in terms of tumor size [centimeter, cm]

研究概览

简要总结

The study would examine by hypericin-supported Fluoreszenzlaparoskopy in terms of tumor size, number and location of the combination of photodynamic diagnosis (PDD) and therapy (PDT) with regard to the detection of peritoneal metastases of locally advanced gastric cancer at 50 adult patients.

详细描述

Hypericin-PDT study is an examination of patients with gastric cancer. The peritoneal carcinosis (PC) of the adult represents the final stage of an advanced tumor and was treated in the past, usually by means of palliative chemotherapy. An improvement in survival for patients with PC could be further improved through the use of maximum cytoreductive surgery (CRS) can be achieved with radical removal of the entire tumor mass and the combination of CRS and intraperitoneal hyperthermic chemotherapy (HIPEC) event-free survival and overall survival. A cure of patients is achieved only in the rarest cases. An essential problem in the treatment of peritoneal carcinomatosis is that can only be poorly differentiated from surrounding tissue due to their location, the tumors often not well recognized because of their size or. This results to differ (as scar tissue) for the surgeon the difficulty between eigentlichem tumor tissue and surrounding tissue.

Through the use of innovative diagnostic and therapeutic options (for example, photodynamic diagnosis (PDD) and therapy (PDT)) above mentioned problems can be improved. In photodynamic diagnosis contrast between tumor and surrounding healthy tissue is improved by an interaction of photodynamic active substance with light of a particular wavelength. The PDT is based on a topical or systemic administration of a photosensitizer (here hypericin), which is irradiated with light of a suitable wavelength and in the presence of oxygen oxygen radicals (with the consequence of a direct cytotoxicity of the tumor cells leading) forms.

The study will be carried out in the Department of General, Visceral and Transplantation Surgery Tübingen at 50 adult patients. The study proposed would examine by hypericin-supported Fluoreszenzlaparoskopy in terms of tumor size, number and location of the combination of photodynamic diagnosis (PDD) and therapy (PDT) with regard to the detection of peritoneal metastases of locally advanced gastric cancer.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • ≥ 18 years
  • Computertomography - morphologically locally - advanced gastric cancer (Classification of Malignant Tumours (TNM): size or direct extent of the primary tumor > 3 or degree of spread to regional lymph nodes positive) without distant metastases (except peritoneum)
  • Histologically confirmed adenocarcinoma of the stomach
  • Karnofsky Index > 70

排除标准

  • Patients who are considered inoperable because of a reduced general condition:
  • Congestive heart failure (New York Heart Association (NYHA) Functional Classification III / IV),
  • Severe coronary heart disease, non-treatable arrhythmia or non-adjustable hypertension,
  • Severe asthma suffering (Chronic obstructive pulmonary disease)
  • Distant metastases except peritoneum
  • Patients with a contraindication related to the present study
  • Allergy or intolerance to the study drug or a substance with chemical similarity to the study medication.
  • Lack of capacity to consent
  • Participation in another interventional therapy studies at intervals of 30 days
  • Contraindication to taking the prescribed study medication the physician's discretion
  • Pregnancy/ Breastfeeding
  • Women in childbearing age who refuse:
  • Simultaneously apply two appropriate contraceptive measures or maintain a full hetero-sexual abstinence at least 28 days prior to the study and for at least 28 days after administration of study medication
  • To stop breast-feeding during the study and through 6 months after the end of study
  • Men who refuse:
  • To use a latex condom during any sexual contact with childbearing women during the study and at least 28 days after completion of study, even if they are successful vasectomy.
  • - Sperm donor to make up at least 28 days after completion of study.-

研究组 & 干预措施

St. John's Wort & PDD, PDT

Experimental

St. John's Wort 900 milligram once oral preoperative & intraoperative irradiation with light (photodynamic diagnosis (PDD) and therapy (PDT), with the appropriate wavelength (390-440 nanometer) over 15 minutes

干预措施: St. John's Wort (Drug)

St. John's Wort & PDD, PDT

Experimental

St. John's Wort 900 milligram once oral preoperative & intraoperative irradiation with light (photodynamic diagnosis (PDD) and therapy (PDT), with the appropriate wavelength (390-440 nanometer) over 15 minutes

干预措施: Photodynamic diagnostic and therapy (Device)

结局指标

主要结局

Peritoneal metastases in terms of tumor size [centimeter, cm]

时间窗: Day 1 (day of surgery)

Detection of peritoneal metastases of locally - advanced gastric cancer by hypericin - supported Fluoreszenzlaparoskopie in terms of tumor size \[cm\]

Peritoneal metastases in terms of number [n]

时间窗: Day 1 (day of surgery)

Detection of peritoneal metastases of locally - advanced gastric cancer by hypericin - supported Fluoreszenzlaparoskopie in terms of number \[n\]

Peritoneal metastases in terms of location

时间窗: Day 1 (day of surgery)

Detection of peritoneal metastases of locally - advanced gastric cancer by hypericin - supported Fluoreszenzlaparoskopie in terms of location \[central, right upper, epigastrium, left upper, , left flank, left lower, pelvis, riht lower, right flank, upper jejunum, lower jejunum, upper ileum, lower illeum\]

次要结局

  • Histological evidence of apoptosis(Day 1 (day of surgery))
  • Hypericin level(Day 1 (day of surgery))

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Prof. Dr. Stefan Beckert

Chief consultant

University Hospital Tuebingen

研究点 (1)

Loading locations...

相似试验

已完成
不适用
Photodynamic diagnostic method using aminolevulinic acid against thoracic malignant tumors
JPRN-jRCTs011180023Kitada Masahiro267
未知
不适用
Intraoperative Photodynamic Diagnosis study by fluorescent labeling with 5-aminolevulinic acid in Endocrine SurgeryThyroid, parathyroid and adrenal diseases
JPRN-UMIN000023246Endocrine surgery, Nippon Medical School60
Unknown
1 期
Intraoperative Dual-modality Imaging in Renal Cell CarcinomaCarcinoma, Renal Cell
NCT02497599Radboud University Medical Center30
Unknown
1 期
Multi-modality Imaging in Peritoneal Carcinomatosis of Colorectal OriginPeritoneal CarcinomatosisCarcinomaNeoplasmsGastrointestinal CancerColorectal Cancer
NCT03699332Radboud University Medical Center29
已完成
1 期
Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck CancerRecurrent Adenoid Cystic Carcinoma of the Oral CavityRecurrent Basal Cell Carcinoma of the LipRecurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal CavityRecurrent Inverted Papilloma of the Paranasal Sinus and Nasal CavityRecurrent Lymphoepithelioma of the NasopharynxRecurrent Lymphoepithelioma of the OropharynxRecurrent Metastatic Squamous Neck Cancer With Occult PrimaryRecurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal CavityRecurrent Mucoepidermoid Carcinoma of the Oral CavityRecurrent Salivary Gland CancerRecurrent Squamous Cell Carcinoma of the HypopharynxRecurrent Squamous Cell Carcinoma of the LarynxRecurrent Squamous Cell Carcinoma of the Lip and Oral CavityRecurrent Squamous Cell Carcinoma of the NasopharynxRecurrent Squamous Cell Carcinoma of the OropharynxRecurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal CavityRecurrent Thyroid CancerRecurrent Verrucous Carcinoma of the LarynxRecurrent Verrucous Carcinoma of the Oral CavityStage I Adenoid Cystic Carcinoma of the Oral CavityStage I Basal Cell Carcinoma of the LipStage I Esthesioneuroblastoma of the Paranasal Sinus and Nasal CavityStage I Follicular Thyroid CancerStage I Inverted Papilloma of the Paranasal Sinus and Nasal CavityStage I Lymphoepithelioma of the NasopharynxStage I Lymphoepithelioma of the OropharynxStage I Midline Lethal Granuloma of the Paranasal Sinus and Nasal CavityStage I Mucoepidermoid Carcinoma of the Oral CavityStage I Papillary Thyroid CancerStage I Salivary Gland CancerStage I Squamous Cell Carcinoma of the HypopharynxStage I Squamous Cell Carcinoma of the LarynxStage I Squamous Cell Carcinoma of the Lip and Oral CavityStage I Squamous Cell Carcinoma of the OropharynxStage I Squamous Cell Carcinoma of the Paranasal Sinus and Nasal CavityStage I Verrucous Carcinoma of the LarynxStage I Verrucous Carcinoma of the Oral CavityStage II Adenoid Cystic Carcinoma of the Oral CavityStage II Basal Cell Carcinoma of the LipStage II Esthesioneuroblastoma of the Paranasal Sinus and Nasal CavityStage II Follicular Thyroid CancerStage II Inverted Papilloma of the Paranasal Sinus and Nasal CavityStage II Lymphoepithelioma of the NasopharynxStage II Lymphoepithelioma of the OropharynxStage II Midline Lethal Granuloma of the Paranasal Sinus and Nasal CavityStage II Mucoepidermoid Carcinoma of the Oral CavityStage II Papillary Thyroid CancerStage II Salivary Gland CancerStage II Squamous Cell Carcinoma of the HypopharynxStage II Squamous Cell Carcinoma of the LarynxStage II Squamous Cell Carcinoma of the Lip and Oral CavityStage II Squamous Cell Carcinoma of the OropharynxStage II Squamous Cell Carcinoma of the Paranasal Sinus and Nasal CavityStage II Verrucous Carcinoma of the LarynxStage II Verrucous Carcinoma of the Oral Cavity
NCT00470496Roswell Park Cancer Institute15